Empagliflozin shows efficacy as stand-alone diabetes treatment

10/4/2013 | Medscape (free registration)

Previously untreated type 2 diabetes patients who either took empagliflozin or sitagliptin showed greater improvements in A1C compared with a placebo group, according to a study in The Lancet Diabetes & Endocrinology. Patients in the empagliflozin arm also showed better fasting plasma glucose and greater reductions in weight, waist size and systolic blood pressure compared with the sitagliptin group, suggesting the drug is effective as monotherapy.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park